WallStSmart
GNLX

Genelux Corporation Common Stock

NASDAQ: GNLX · HEALTHCARE · BIOTECHNOLOGY

$3.19
+1.69% today

Updated 2026-06-03

Market cap
$131.38M
P/E ratio
P/S ratio
16,422.80x
EPS (TTM)
$-0.85
Dividend yield
52W range
$2 – $9
Volume
0.2M

Genelux Corporation Common Stock (GNLX) Financial statements

SEC filings — annual and quarterly data.

Cash flow — annual

Item2019202020212022202320242025
Operating cash flow$-7.22M$-7.21M$-6.58M$-3.57M$-20.27M$-21.23M$-25.27M
Capital expenditures$1.77M$20000.00$49000.00$49000.00$1.02M$381000.00$1.10M
Depreciation
Stock-based comp$5.33M$4.27M$2.42M$5.20M$6.07M$5.87M
Free cash flow$-8.99M$-7.22M$-6.63M$-3.62M$-21.30M$-21.61M$-26.37M
Investing cash flow
Financing cash flow
Dividends paid
Share repurchases
Debt repayment
Net change in cash

Frequently asked questions

What is Genelux Corporation Common Stock's revenue?

Genelux Corporation Common Stock's trailing twelve-month revenue is $8000.00. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.

How profitable is GNLX?

In its most recent fiscal year, GNLX ran a gross margin of -7,075.00%, an operating margin of -415,175.00%, and a net margin of -401,812.50%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.

How much free cash flow does GNLX generate?

GNLX produced $-26.37M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is GNLX's balance sheet healthy?

GNLX holds $5.33M in cash and equivalents against — in long-term debt, on $11.54M of shareholder equity. That debt is best read against the cash flow the business throws off each year.